AstraZeneca, Merck Say Lynparza Demonstrates Long-Term Progression-Free Survival Benefit
September 18 2020 - 10:35AM
Dow Jones News
By Michael Dabaie
AstraZeneca and Merck & Co. said Lynparza demonstrated a
long-term progression-free survival benefit versus placebo.
The companies said Lynparza demonstrated a long-term
progression-free survival benefit versus placebo as a first-line
maintenance treatment in patients with newly diagnosed, advanced
BRCA-mutated ovarian cancer who had a complete or partial response
following platinum-based chemotherapy.
Five-year follow-up data from the Phase III SOLO-1 trial showed
Lynparza reduced the risk of disease progression or death by 67%
and improved progression-free survival to a median of 56.0 months
versus 13.8 months for placebo.
At five years, 48.3% of patients treated with Lynparza remained
free from disease progression versus 20.5% on placebo.
The median duration of treatment with Lynparza was 24.6 months,
versus 13.9 months with placebo, the companies said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
September 18, 2020 10:20 ET (14:20 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024